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Abstract: The aim of this study was to evaluate regulatory T lymphocytes (Tregs) in the course of allergic
contact dermatitis (ACD) and to elucidate the role of IL-10 and TGF-b in Tregs activity. Peripheral blood
CD4+CD25+ and CD4+CD25high cells were determined by flow cytometry in patients with acute disseminated
ACD (‘ad’, n = 36), acute localized ACD (‘al’, n = 26), and disseminated ACD during remission (‘rd’, n = 27)
as well as in controls (n = 22). Serum levels of cytokines were measured using ELISA. The mean percentage of
CD4+CD25+ and CD4+CD25high cells in patients with ad ACD was significantly higher than in controls
(p < 0.01) and the remaining patients (p < 0.05). Both cell populations were significantly elevated in persons
with widespread skin lesions (p < 0.05). In ad patients the CD4+CD25+ increased during three weeks of
disease, although the significant increase of CD4+CD25high was noted only in the third week. Patients with ad
ACD showed a significantly decreased serum level of TGF-b1 as compared with controls and the remaining
ACD patients. IL-10 level did not differ between all groups. The elevated population of CD4+CD25high cells in
ad ACD patients, and its dependence on the extension of skin lesions, suggest a role of Tregs in regulating the
course of ACD. The growing Tregs percentages may indicate their peripheral generation during ACD. The
development of lesions despite an increased population of Tregs suggests their functional defect. The role of
TGF-b1 in the suppressive activity of Tregs cannot be excluded. (Folia Histochemica et Cytobiologica 2011;
Vol. 49, No. 2, pp. 255–262)
Key words: allergic contact dermatitis, clinical course, regulation, regulatory T lymphocytes
Introduction
Allergic contact dermatitis (ACD) is an antigen-spe-
cific, T cell-dependent inflammatory skin disease,
which develops as a result of contact with hapten in
allergic persons. The allergic reaction occurs in two
phases: sensitization and elicitation. The Langerhans’
cells (LC) play a key role in the development of ACD:
they process the allergen and present it to T cells in
draining lymph nodes (DLN). The migration and mat-
uration of LC are initiated and regulated by cytok-
ines in epidermis: tumor necrosis factor (TNF)-a, In-
terleukin (IL)-1b, IL-12 and granulocyte macroph-
age-colony stimulating factor (GM-CSF) [1–3]. In the
elicitation (effector) phase of ACD, specific T cells,
both CD4+ and CD8+, proliferate and when activat-
ed, secrete inflammatory cytokines (IL-2, IFN-g)
which also activate keratinocytes. Keratinocytes express
intracellular cell adhesion molecule-1 (ICAM-1),
which allows for the cells to interact with T lympho-
cytes. These cells also express molecule HLA-DR,
which allows the presentation of antigen to T lympho-
cytes. Activated keratinocytes produce cytokines: IL-1,
IL-6, GM-CSF, which recruit and activate T cells.
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The clinical effect of the contact hypersensitivity
reaction is an inflammatory process in the skin. Most
frequently, skin lesions are limited to the area of con-
tact with the allergen (stage I) or spread to the near-
est areas (stage II). In rare cases, lesions are dissem-
inated or generalized (stage III) [4–6].
Regulatory T lymphocytes (Tregs) are a subset of
T cells population with immunosuppressive activity.
It has been shown that Tregs have a role in the regu-
lation of the Th1 and Th2 activity, a role in defend-
ing against infections and neoplasms, and in main-
taining immunological self-tolerance [7–11].
To date, two main types of Tregs have been de-
scribed: natural Tregs, and induced or adaptive Tregs.
Natural Tregs are physiologically produced by the
thymus; they constitutively express the interleukin
(IL)-2 receptor a chain (CD25), [12]. The marker of
the natural Tregs is the transcription factor forkhead
box P3 (FOXP3); its expression is necessary for the
development and suppressive function of the cells
[13–15]. Adaptive Tregs are induced from native
T cells by a specific mode of antigen stimulation, es-
pecially in a particular cytokine milieu [16, 17]. They
include Tregs which secrete IL-10 (Tr1), cells secret-
ing transforming growth factor (TGF)-b T helper
(Th)3, g/d T cell Receptor (TCR)-expressing
CD4–CD8– T cells and CD8+CD28– T cells [15, 18].
Lymphocytes CD4+CD25+ may have different de-
grees of CD25 expression. The population of Tregs
FoxP3+ cells is identified as CD4+ cells with a high
degree of CD25 expression (CD4+CD25high) [14].
The role of Tregs in allergic contact dermatitis
has been studied in experimental conditions in vit-
ro or in animal models, but in humans it has been
evaluated mainly on patch test reactions [19–23].
This is why the examinations concern only the in-
duction phase or the very early stage of effector
phase of ACD and very limited (only one small skin
lesion) form of disease.
The aim of this study was to evaluate the role of
the regulatory T lymphocytes (Tregs) in allergic con-
tact dermatitis (ACD) and the relationships between
Tregs and the clinical course of disease, as well as to
elucidate the significance of IL-10 and TGF-b in the
suppressive Tregs activity.
Material and methods
Three groups of patients with allergic contact dermatitis
(n = 89) and a group of healthy persons as a control group
(n = 22) were enrolled in this study. The first group of ACD
patients (group I, n = 36) consisted of persons with acute
disseminated form of eczema (ad). The second group of
patients comprised those with disseminated skin lesions
during remission (group II, n = 27, rd). The third group
included patients with acute eczema limited to one lesion
(group III, n = 26, al). The diagnosis of ACD was estab-
lished in each patient on the basis of thoroughly taken his-
tory of disease before and after patch testing and clinical
examination. The extent and severity of skin lesions were
calculated using the eczema area and severity index (EASI)
scoring system for assessing the activity of AD, elaborated
by Hanifin [24], adapted by authors for assessing severity of
skin lesions in ACD and described in detail elsewhere [25].
None of the patients included in this study had clinical symp-
toms or laboratory signs of skin bacterial infection, nor had
they been taking corticosteroids and any other immunotro-
pic medication for at least four weeks.
The analysis of peripheral blood leukocytes was made
using a hematological analyzer (MAXM, Beckman Coulter).
The value of leukocytes was presented in G/L, and lympho-
cytes presented in percentages (%) and in absolute values
(G/L). Subpopulations of peripheral blood lymphocytes
were calculated using flow cytometry (Coulter Cytomics FC
500). The surface markers on lymphocytes were detected
by incubation with the appropriate monoclonal antibodies
(mAbs): anti-CD3 (phycoerythrin-cyanin 5, PECy5 conju-
gated), anti-CD4 (phycoerithrin-cyanin, PECy conjugated),
anti-CD25 (phycoerithrin Red, ECD conjugated), (Dako,
Denmark). Serum levels of cytokines (IL-10 and TGF-b)
were measured using ELISA with the commercially avail-
able enzyme-linked immunosorbent assay kit (Quantikine,
R&D Systems, Minneapolis, MN, USA).
Statistical analysis. Results were presented as a mean of
the absolute values and as a mean of the percentage of
CD4+CD25+ and CD4+CD25high and SD, calculated on the
basis of leukogram. Data was compared between all groups
of ACD patients and healthy persons using two-tail, non
paired t-test. Pearson’s correlation test was used to assess
the correlation between the percentage of peripheral blood
CD4+CD25+ and CD4+CD25high cells. A p value of less than
0.05 was regarded as significant.
Results
Eighty nine patients (42 women and 47 men, mean
age 46.1 ± 14.6 years, range 20–84) with allergic con-
tact dermatitis, and 22 healthy persons as a control
(13 women and nine men, mean age 41.4 ± 15.6 years,
range 23–82) participated in this study. The charac-
teristics of the examined and control groups are pre-
sented in Table 1.
The mean percentage of CD4+CD25+ and
CD4+CD25high cells in patients with acute dissemi-
nated lesions was significantly higher than in the con-
trol group (p < 0.01) and in the remaining ACD pa-
tients (p < 0.05), (Figures 1 and 2). There was a pos-
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Table 1. Characteristics of allergic contact dermatitis patients and control group
Patients with disseminated
Patients withform of ACD  
localized ACD (al)
Control (c) p
Acute (ad) Remission (dr)
n 36 26 27 22 –
Sex (f/m) 13/23 12/14 17/10 13/9 –
Age (years) ad vs. c, p = 0.084
Mean ± SD 48.8 ± 15.5 47.9 ± 16.3 42.4 ± 12.0 41.4 ± 15.6 dr vs. c, p = 0.167
Range 20–84 20–82 21–65 23–82 al vs. c, p = 0.860
Duration of disease ad vs. dr, p = 0.307
(years)
Mean ± SD 7.3 ± 9.1 5.2 ± 5.9 6.4 ± 5.6 – ad vs. al, p = 0.652
Range 1 month –30 years 3 months –20 years 6 months –21 years dr vs. al, p = 0.451
Duration of present
lesions (weeks)
Mean ± SD 2.97 ± 1.7 – 2.85 ± 1.4 – ad vs. dr, p = 0.766
Range 3 days – 8 weeks 1–7 weeks
EASI* score
Mean ± SD 26.3 ± 15.3 19.5 ± 13.9 < 5 – ad vs. dr, p = 0.078
Range 5–61.8 5.3–34.8
*EASI — Eczema Area and Severity Index
itive correlation between the percentage of
CD4+CD25+ cells and CD4+CD25high (p < 0.001)
(Figure 3). In patients with disseminated acute ACD,
the percentage of both CD4+CD25+ and
CD4+CD425high cells in peripheral blood varied de-
pending on the duration time of skin lesions. In pa-
tients in whom the skin lesions lasted one week or
less, the blood populations of CD4+CD25+ and
CD4+CD25high cells were lowest. In patients exam-
ined in subsequent weeks of the disease, the popula-
tion of CD4+CD25+ cells was higher during three
weeks of the disease, whereas the elevated percent-
age of CD4+CD25high cells was seen in patients ex-
amined in the third week of the disease (Figures 4
and 5). The values of both CD4+CD25+ and
CD4+CD25high populations were significantly higher
in patients with widespread lesions (EASI > 16
scores) as compared with persons with a single skin
lesion, (p < 0.05 and p < 0.01, respectively) (Figures
6 and 7). Patients with acute disseminated ACD
showed significantly decreased serum level of TGF-b1
as compared with healthy persons and the remaining
Figure 1. Percentage of lymphocytes CD4+CD25+ in
peripheral blood in patients with allergic contact
dermatitis and control group Figure 2. Percentage of CD4+ lymphocytes with high
expression of CD25 in patients with allergic contact
dermatitis and control group
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eczema patients, whereas IL-10 mean serum level did
not differ in all groups examined (Tables 2 and 3).
Discussion
Using the Fluorescence Activated Cell Sorting
(FACS) method, it has been stated that the values of
the CD4+CD25high cells range from 1.7% [14] to 2.1%
[26] of CD4+CD25+ T lymphocytes in the peripheral
blood of an adult human. Similar values have been
found in examined healthy controls, as well as in ACD
patients with a localized form of disease, and in pa-
tients in remission.
Recent studies have shown that in healthy per-
sons the lack of contact allergy results in active sup-
pression of hapten-specific effector cells through reg-
ulatory CD4+ cells secreting IL-10. Lymphocytes
CD4+ specific to nickel were ascertained both in peo-
ple with an allergy to nickel and in healthy people,
but specific CD8+ lymphocytes have been found only
in nickel allergy patients [20, 27]. In further experi-
ments, Cavani et al. showed that CD4+ cells isolated
from healthy people did not proliferate after nickel
stimulation in vitro, whereas removing the subpopu-
lation of CD4+CD25+ retrieved this ability [28].
Figure 3. Correlation between percentage of lymphocytes
CD4+CD25+ and CD4+CD25high. Pearson correlation
coefficient r = 0.84 (p < 0.001)
Figure 4. Percentage of CD4+CD25+ lymphocytes in
peripheral blood in ACD patients and control group
depending on duration of disease
Figure 5. Percentage of CD4+CD25high lymphocytes in
peripheral blood in ACD patients and control group
depending on duration of disease
Figure 6. Percentage of CD4+CD25+ lymphocytes
depending on extension of skin lesions
Figure 7. Percentage of CD4+CD25high lymphocytes
depending on extension of skin lesions
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In the ACD patients with acute stage disease, the
percentage of peripheral blood CD4+CD25high cells
was significantly higher than in healthy controls and
in the remaining groups of contact eczema patients.
To the best of our knowledge, no similar studies of
ACD patients have been performed. In the scarce lit-
erature data regarding patients with atopic dermati-
tis (AD), an increased number of Tregs has been
found in peripheral blood [29, 30], while results of
another study showed a diminished population of
Tregs [31].
Subpopulation of CD4+CD25+ can represent both
regulatory T cells and activated effector CD4+ T cells,
which may also transiently express the CD25 mole-
cule [11, 32], so that only CD4+CD25high population
should be taken into account as Tregs.
It is difficult to determine the source of Tregs de-
tected in the blood of patients with ACD, but it is
possible that CD4+CD25high appear on the periphery
from CD4+CD25+ or from CD4+CD25– cells after
antigen stimulation, which shows the earlier growth
of the total population of CD4+ (data not shown) and
CD4+CD25+ than CD4+CD25high cells. The percent-
ages of both CD4+ and CD4+CD25+ populations
were significantly higher in the peripheral blood of
ad ACD patients examined in the second and third
weeks of the disease compared to the earlier values,
whereas a significantly increased percentage of
CD4+CD25high was seen later in the natural course of
ACD. A study of skin specimens from the area of
positive patch tests which were examined in consecu-
tive days after allergen challenge [33], showed that
skin infiltration of CD4+ cells preceded that of
CD4+CD25+ and thus confirmed the above-men-
tioned observations. This may mean a delayed inflow
of CD4+CD25+ cells from the blood, or it may sug-
gest that they can emerge in the skin during 48 hours
from these CD4+ lymphocytes T, which penetrated
skin earlier. However, it has been recently shown
that Tregs reside in normal human skin, from where
they can be isolated and expanded. These cells ex-
press high levels of CD25, L-selectin, GITR, FoxP3,
CTLA-4 and CLA [34]. Another study using immu-
nohistochemical staining of skin specimens from
human ACD lesions found that a significant num-
ber of epidermal as well as dermal CD3+, CD4+ and
CD25+ cells were FoxP3+ [32]. In the most recent
study, Tomura et al. showed in the murine CHS
model a marked increase of CD4+ Tregs after aller-
gen challenge both in the skin and in draining lymph
nodes. The authors found that, in steady state, Tregs
recirculate bidirectionally between skin and lymph
nodes and that this Tregs traffic is substantially en-
hanced during CHS reaction, especially in the elic-
itation phase. These results may indirectly explain
the increased amount of CD4+CD25high in the pe-
ripheral blood of our examined patients with acute
disseminated ACD. These detected cells may be of
the Tregs recirculating to skin from DLNs. Tomura
et al. demonstrated that skin-derived Tregs have
a stronger inhibitory effect on hapten-specific T-cell
proliferation than LN-resident Tregs, and they in-
hibit local cutaneous immune response in situ. In
a further study, the authors found that Tregs migrat-
ing from the skin (but not from LN) contain a frac-
tion of CD4+CD25high population with strong immu-
nosuppressive activity. These cells were seen in the
challenged local skin but few in the unchallenged
skin [35].
The role of CD4+CD25high in the course of ACD
inflammatory reaction is supported also by the fact
of dependence between the percentage of
Table 2. Mean serum level of IL-10 in patients with allergic contact dermatitis and control group
Concentration Patients with Patients with Control          p
of IL-10 [pg/ml] disseminated ACD limited ACD (al) group (c)
Acute (ad) Remission (rd)
Mean ± SD 4.84 ± 3.2 3.6 ± 2.8 3.5 ± 2.6 4.21 ± 2.9 ad vs. c, p = 0.455
rd vs. c, p = 0.463
al vs. c, p = 0.371
Table 3. Mean serum level of TGF-b1 in patients with allergic contact dermatitis and control group
Concentration Patients with Patients with Control p
of TGF-b1 (pg/ml) disseminated ACD limited ACD (al) group (c)
Acute (ad) Remission (rd)
Mean ± SD 22,821 ± 17,732 29,234 ± 22,906 30,394 ± 16,358 32,301 ± 15,632 ad vs. c, p = 0.034
rd vs. c, p = 0.595
al vs. c, p = 0.683
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CD4+CD25high and degree of the skin lesions exten-
sion. In patients with considerable skin lesions (EASI ≥
≥ 16 scores), the percentage of peripheral blood
CD4+CD25high was significantly higher than in those
with a mild form of the disease (p < 0.01).
The development of skin lesions, despite the high-
er percentage of CD4+CD25high, may indicate an in-
sufficient role and the breakdown of the mechanisms
related to Tregs, which suppress the inflammatory
process in the skin. The increased population of Tregs
CD4+CD25high is not translated simply into their ac-
tivity, which suggests the presence of their functional
defect or potent mechanisms of suppression of their
activity. Cavani et al. showed that Tregs originating
from the blood of eczema patients exerted a decreased
activity in suppressing hapten-specific answers of both
CD4+ and CD8+ cells [28]. It has been shown that
Tregs can block APC-depending, hapten-specific ef-
fector reaction of T lymphocytes and probably also
play a role in completing the eczema inflammatory
skin reaction in ACD patients [33].
The significant role of IL-10 in the suppressive
activity of Tregs is not yet fully established,  because
of discrepancies in the literature data. It has been
shown that Tregs exert their activity by mechanisms
depending on direct contact of cells, independently
of cytokines [14, 36–38]. Other data suggests that
Tregs are able to produce great amounts of IL-10,
when antigenic stimulation proceeds in defined con-
ditions [39–42]. In our patients, there were no signif-
icant differences in serum levels of IL-10 between
ACD patients and healthy controls, nor between the
remaining groups examined. There was also no cor-
relation between serum concentrations of IL-10 and
the percentage of CD4+CD25high, which could sug-
gest either that in those patients the suppressive ac-
tivity of Tregs is independent of IL-10 secretion, or
that increased amount of this cytokine does not de-
pend simply on the magnitude of the Tregs popula-
tion. IL-10 can also originate from cells other than
Tregs, and its activity can occur only locally.
There is also a lack of unequivocal data concern-
ing the role of TGF-b in the suppressive activity of
regulatory T lymphocytes. There is evidence for par-
ticipation of that cytokine in maintenance of Tregs
on the periphery and stimulation of their generation
from native T lymphocytes. The surface expression
of latency associated protein (LAP), the precursor of
TGFb, was shown on activated Tregs (stimulated by
anti-CD3/CD28 antibodies), [43]. The marked role
of soluble TGF-b, together with membrane CTLA-4,
in providing the suppressor signal has been demon-
strated [44]. In experiments on mice and in humans,
the role of connected activity of CTLA-4 and mem-
brane form of TGF-b (mTGF-b) in the blocking of
proliferation and function of effector CD4+ and
CD8+ T lymphocytes [45] has been shown. Experi-
ments from recent years seem to confirm the role of
TGF-b in the suppressive activity of CD4+CD25+ T
cells, both in humans and in animals [37, 46]. It has
been shown that Tregs not only express the mem-
brane inactive form of TGF-b, but also the active
form of this cytokine [47].
ACD patients with the acute stage of disseminat-
ed form of the disease showed a significantly de-
creased mean serum level of TGF-b in comparison
with healthy controls. The diminished level of serum
TGF-b, despite the elevated percentage of
CD4+CD25high lymphocytes T, may indicate an inabil-
ity of Tregs to produce sufficient amout of TGF-b in
ACD patients. It may also suggest that this cytokine
can be produced by cells other than Tregs.
Data from other authors, and our results, indi-
cate that the increased percentage of CD4+ lympho-
cytes T with expression CD25 molecule and with
high expression of CD25, seen in patients with acute
stage allergic contact dermatitis, as well as the de-
pendence of a percentage of these cells on the ex-
tension of skin lesions, suggest a role for Tregs in
regulating the course of ACD. The growing percent-
age of the CD4+CD25high during the course of aller-
gic contact dermatitis may indicate their generation
on the periphery during the effector phase of the
disease. Development of the skin eczematous inflam-
matory lesions despite the increased population of
T regulatory cells (CD4+CD25high) suggests function-
al defect of these cells or strongly expressed mecha-
nisms blocking of their activity. It is possible that
TGF-b participates in the suppressive activity of
CD4+CD25high regulatory T lymphocytes in allergic
contact dermatitis.
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